RESUMO
Gallbladder mucocele (GBM) is a common extra-hepatic biliary syndrome in dogs with death rates ranging from 7 to 45%. Therefore, the aim of this study was to identify the association of survival with variables that could be utilized to improve clinical decisions. A total of 1194 dogs with a gross and histopathological diagnosis of GBM were included from 41 veterinary referral hospitals in this retrospective study. Dogs with GBM that demonstrated abnormal clinical signs had significantly greater odds of death than subclinical dogs in a univariable analysis (OR, 4.2; 95% CI, 2.14-8.23; P<0.001). The multivariable model indicated that categorical variables including owner recognition of jaundice (OR, 2.12; 95% CI, 1.19-3.77; P=0.011), concurrent hyperadrenocorticism (OR 1.94; 95% CI, 1.08-3.47; P=0.026), and Pomeranian breed (OR, 2.46; 95% CI 1.10-5.50; P=0.029) were associated with increased odds of death, and vomiting was associated with decreased odds of death (OR, 0.48; 95% CI, 0.30-0.72; P=0.001). Continuous variables in the multivariable model, total serum/plasma bilirubin concentration (OR, 1.03; 95% CI, 1.01-1.04; P<0.001) and age (OR, 1.17; 95% CI, 1.08-1.26; P<0.001), were associated with increased odds of death. The clinical utility of total serum/plasma bilirubin concentration as a biomarker to predict death was poor with a sensitivity of 0.61 (95% CI, 0.54-0.69) and a specificity of 0.63 (95% CI, 0.59-0.66). This study identified several prognostic variables in dogs with GBM including total serum/plasma bilirubin concentration, age, clinical signs, concurrent hyperadrenocorticism, and the Pomeranian breed. The presence of hypothyroidism or diabetes mellitus did not impact outcome in this study.
Assuntos
Doenças do Cão/diagnóstico , Doenças da Vesícula Biliar/veterinária , Hiperbilirrubinemia/veterinária , Mucocele/veterinária , Hiperfunção Adrenocortical/veterinária , Animais , Bilirrubina/sangue , Biomarcadores , Doenças do Cão/mortalidade , Doenças do Cão/cirurgia , Cães , Doenças da Vesícula Biliar/diagnóstico , Doenças da Vesícula Biliar/mortalidade , Doenças da Vesícula Biliar/cirurgia , Predisposição Genética para Doença , Hiperlipidemias/veterinária , Mucocele/diagnóstico , Mucocele/mortalidade , Mucocele/cirurgia , Estudos Retrospectivos , Resultado do TratamentoAssuntos
Transplante de Medula Óssea , Imunologia de Transplantes , Transplante Homólogo/imunologia , Seguimentos , Rejeição de Enxerto/epidemiologia , Transplante de Coração/imunologia , Humanos , Terapia de Imunossupressão/métodos , Transplante das Ilhotas Pancreáticas/imunologia , Transplante de Rim/imunologia , Transplante de Fígado/imunologia , Transplante de Pulmão/imunologia , Ativação Linfocitária , Teste de Cultura Mista de Linfócitos , Transplante de Pâncreas/imunologia , Fatores de Tempo , Doadores de Tecidos , Quimeras de TransplanteAssuntos
Transplante de Medula Óssea/imunologia , Terapia de Imunossupressão/métodos , Linfócitos/imunologia , Imunologia de Transplantes , Quimera/imunologia , Feminino , Citometria de Fluxo , Antígenos HLA/análise , Transplante de Coração/imunologia , Humanos , Hibridização in Situ Fluorescente , Transplante das Ilhotas Pancreáticas/imunologia , Transplante de Rim/imunologia , Transplante de Fígado/imunologia , Ativação Linfocitária , Teste de Cultura Mista de Linfócitos , Masculino , Monitorização Imunológica , Reação em Cadeia da Polimerase , Prednisona/uso terapêutico , Tacrolimo/uso terapêutico , Cromossomo YRESUMO
It has been postulated that the resident "passenger" leukocytes of hematolymphoid origin that migrate from whole organ grafts and subsequently establish systemic chimerism are essential for graft acceptance and the induction of donor-specific nonreactivity. This phenomenon was augmented by infusing 3 x 10(8) unmodified donor bone-marrow cells into 40 patients at the time of organ transplantation. Fifteen of the first 18 analyzable patients had sequential immunological evaluation over postoperative intervals of 5 to 17 months, (which included 7 kidney (two with islets), 7 liver (one with islets), and one heart recipient). The evolution of changes was compared with that in 16 kidney and liver nonmarrow controls followed for 4 to 5 months. The generic immune reactivity of peripheral blood mononuclear cells (PBMC) was determined by their proliferative responses to mitogens (PHA, ConA). Alloreactivity was measured by the recipient mixed lymphocyte reaction (MLR) to donor and HLA-mismatched third-party panel cells. Based on all 3 tests, the recipients were classified as donor-specific hyporeactive, intermediate, and responsive; patients who were globally suppressed made up a fourth category. Eight (53%) of the 15 marrow-treated recipients exhibited progressive modulation of donor-specific reactivity (3 hyporeactive and 5 intermediate) while 7 remained antidonor-responsive. In the nonmarrow controls, 2 (12.5%) of the 16 patients showed donor-specific hyporeactivity, 10 (62.5%) were reactive, and 4 (25%) studied during a CMV infection had global suppression of responsiveness to all stimuli.